This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third View: Delving into the topline data from the Phase 2 clinical trial of NBI-1117568 in adults with schizophrenia

Ticker(s): NBIX

Who's the expert?

Institution: Jack Vaeth, MD, PA

  • Board certified in Adult and Adolescent Psychiatry 
  • Experiences include inpatient and outpatient care with interests in psychopharmacotherapy, adolescent psychiatry, women’s mental health issues, compulsive gambling, and brain stimulation techniques (ECT, VNS & TMS) in the treatment of resistant mood disorders
  • interested and up to date on literatue for the use and potential of psilocybin in depression, including COMP360

Interview Goal
to discuss the current treatment landscape and the potential of NBI-1117568, an M4 selective orthosteric agonist being developed by Neurocrine for the treatment of schizophrenia.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.